|
|
GEO help: Mouse over screen elements for information. |
|
Status |
Public on Jun 05, 2024 |
Title |
Arachidonic acid mobilization and peroxidation promote microglial dysfunction in Aβ pathology |
Organism |
Mus musculus |
Experiment type |
Expression profiling by high throughput sequencing
|
Summary |
Aberrant increase of arachidonic acid (ARA) has long been implicated in the pathology of Alzheimer's disease (AD), while the underlying causal mechanism remains unclear. In this study, we revealed a link between ARA mobilization and microglial dysfunction in Aβ pathology. Lipidomic analysis of primary microglia from AppNL-GF mice showed a marked increase in free ARA and lysophospholipids (LPLs) along with a decrease in ARA-containing phospholipids, suggesting increased ARA release from phospholipids (PLs). To manipulate ARA-containing PLs in microglia, we genetically deleted Lysophosphatidylcholine Acyltransferase 3 (Lpcat3), the main enzyme catalyzing the incorporation of ARA into PLs. Loss of microglial Lpcat3 reduced the levels of ARA-containing phospholipids, free ARA and LPLs, leading to a compensatory increase in monounsaturated fatty acid (MUFA)-containing PLs in the AppNL-GF mice. Notably, the reduction of ARA in microglia significantly ameliorated oxidative stress and inflammatory responses while enhancing the phagocytosis of Aβ plaques and promoting the compaction of Aβ deposits. Mechanistically, sc-RNA seq suggested that LPCAT3 deficiency facilitates phagocytosis by facilitating de novo lipid synthesis while protecting microglia from oxidative damage. Collectively, our study reveals a novel mechanistic link between ARA mobilization and microglial dysfunction in AD. Lowering brain ARA levels through pharmacological or dietary interventions may be a potential therapeutic strategy to slow down AD progression.
|
|
|
Overall design |
To manipulate ARA-containing PLs in microglia, we genetically deleted Lysophosphatidylcholine Acyltransferase 3 (Lpcat3), the main enzyme catalyzing the incorporation of ARA into PLs. We analyzed the impact of Lpcat3 deletion on microgllia response to Aβ pathology using immunostaining, bulk and single-cell RNA seq, and flow cytometry.
|
|
|
Contributor(s) |
Lin D, Gao J |
Citation(s) |
38866484 |
NIH grant(s) |
Grant ID |
Grant title |
Affiliation |
Name |
R01 AG073310 |
Targeting IDOL-ApoE receptor pathway in Alzheimer's disease |
OHIO STATE UNIVERSITY |
Jie Gao |
|
|
Submission date |
May 31, 2024 |
Last update date |
Sep 04, 2024 |
Contact name |
Jie Gao |
E-mail(s) |
Jie.Gao@osumc.edu
|
Organization name |
The Ohio State University
|
Department |
The Department of Neuroscience
|
Lab |
Gao Lab
|
Street address |
460 W. 12th Ave
|
City |
Columbus |
State/province |
OH |
ZIP/Postal code |
43210 |
Country |
USA |
|
|
Platforms (1) |
GPL17021 |
Illumina HiSeq 2500 (Mus musculus) |
|
Samples (13)
|
GSM8301015 |
Hippocampus from AppNL-G-F; Lpcat3 f/f; vav1-CRE, 9 mo; 3283 |
GSM8301016 |
Hippocampus from AppNL-G-F; Lpcat3 f/f; vav1-CRE, 9 mo; 3284 |
GSM8301017 |
Hippocampus from AppNL-G-F; Lpcat3 f/f; vav1-CRE, 9 mo; 3285 |
GSM8301018 |
Hippocampus from AppNL-G-F; Lpcat3 f/f; vav1-CRE, 9 mo; 3286 |
GSM8301019 |
Hippocampus from AppNL-G-F; Lpcat3 f/f, 9 mo; 3287 |
GSM8301020 |
Hippocampus from AppNL-G-F; Lpcat3 f/f; vav1-CRE, 9 mo; 3288 |
GSM8301021 |
Hippocampus from AppNL-G-F; Lpcat3 f/f, 9 mo; 3296 |
GSM8301022 |
Hippocampus from AppNL-G-F; Lpcat3 f/f, 9 mo; 3297 |
GSM8301023 |
Hippocampus from AppNL-G-F; Lpcat3 f/f, 9 mo; 3298 |
GSM8301024 |
Hippocampus from AppNL-G-F; Lpcat3 f/f; vav1-CRE, 9 mo; 3300 |
GSM8301025 |
Hippocampus from AppNL-G-F; Lpcat3 f/f; vav1-CRE, 9 mo; 4301 |
GSM8301026 |
Hippocampus from AppNL-G-F; Lpcat3 f/f, 9 mo; 4306 |
GSM8301027 |
Hippocampus from AppNL-G-F; Lpcat3 f/f, 9 mo; 4307 |
|
Relations |
BioProject |
PRJNA1118825 |
Supplementary file |
Size |
Download |
File type/resource |
GSE268838_ProcessedData_CountMatrix.txt.gz |
940.3 Kb |
(ftp)(http) |
TXT |
SRA Run Selector |
Raw data are available in SRA |
|
|
|
|
|